Theratechnologies Inc
TSX:TH

Watchlist Manager
Theratechnologies Inc Logo
Theratechnologies Inc
TSX:TH
Watchlist
Price: 4.47 CAD -4.89% Market Closed
Market Cap: 205.5m CAD

Theratechnologies Inc
Cash from Financing Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Theratechnologies Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Theratechnologies Inc
TSX:TH
Cash from Financing Activities
-$22.8m
CAGR 3-Years
-36%
CAGR 5-Years
-27%
CAGR 10-Years
-46%
Repare Therapeutics Inc
NASDAQ:RPTX
Cash from Financing Activities
$110k
CAGR 3-Years
-90%
CAGR 5-Years
-79%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Cash from Financing Activities
-$127.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Cash from Financing Activities
$15.7m
CAGR 3-Years
-70%
CAGR 5-Years
-33%
CAGR 10-Years
-10%
Willow Biosciences Inc
TSX:WLLW
Cash from Financing Activities
CA$735k
CAGR 3-Years
N/A
CAGR 5-Years
-54%
CAGR 10-Years
N/A
Spectral Medical Inc
TSX:EDT
Cash from Financing Activities
CA$5.1m
CAGR 3-Years
-17%
CAGR 5-Years
-2%
CAGR 10-Years
-12%
No Stocks Found

Theratechnologies Inc
Glance View

Market Cap
205.5m CAD
Industry
Biotechnology

Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 87 full-time employees. The firm has two approved products: EGRIFTA SV in the United States, and Trogarzo in the United States, the European Union and the United Kingdom. EGRIFTA SV (tesamorelin for injection) is developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Trogarzo (ibalizumab-uiyk) is developed for HIV treatment. The treatment is infused every two weeks. The company is a new class of antiretrovirals (ARV), and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs. The firm markets its prescription products in the United States, Europe and Canada. Its research pipeline is focused on specialized therapies addressing unmet medical needs in HIV, oncology and non-alcoholic steatohepatitis (NASH).

TH Intrinsic Value
5.7 CAD
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Theratechnologies Inc's Cash from Financing Activities?
Cash from Financing Activities
-22.8m USD

Based on the financial report for May 31, 2025, Theratechnologies Inc's Cash from Financing Activities amounts to -22.8m USD.

What is Theratechnologies Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-46%

The average annual Cash from Financing Activities growth rates for Theratechnologies Inc have been -36% over the past three years , -27% over the past five years , and -46% over the past ten years .

Back to Top